Value of lncRNA LINC00641 as a Potential Biomarker for Diagnosis of Alzheimer’s Disease and Elucidation of its Underlying Molecular Mechanism
Journal of Molecular Neuroscience · 04.03.2026 · 76 (1)
DOI: 10.1007/s12031-026-02484-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Molecular Neuroscience, online erschienen am 04.03.2026. Verfasst von Lihong Ren und 3 weiteren Autor:innen. Beteiligte Einrichtung: Geriatrics Department, Nantong Hospital of Traditional Chinese Medicine, Nantong City, Jiangsu Province, China. Hauptthemen laut MEDLINE: Alzheimer Disease, RNA, Long Noncoding. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Nantong Municipal Science and Technology Bureau Social Democracy Science and Technology Project.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) is a neurodegenerative disease with progressive cognitive impairment as the main clinical manifestation. Long non-coding RNAs (lncRNAs) are crucial regulators of diverse cellular processes. This study examined the clinical significance and underlying mechanisms of LINC00641 in AD diagnosis. qRT-PCR was used to measure plasma LINC00641 levels in AD patients, and its diagnostic value was assessed using ROC curve. Cell proliferation was measured via the CCK-8 assay. Apoptosis and AD-related proteins were detected by ELISA. The interaction between LINC00641 and its downstream target miR-501-3p was validated through online network prediction and dual-luciferase reporter assay. Plasma LINC00641 expression was lower in AD patients than in controls. It correlated positively with Aβ42 and negatively with p-Tau181 and p-Tau217. Combining of LINC00641 with clinical markers obviously improved diagnostic accuracy for distinguishing AD patients. Overexpression of LINC00641 restored the viability of H19-7 cells after Aβ42 treatment, and reduced levels of cleaved Caspase-3, Aβ42, p-Tau181/Tau, and p-Tau217/Tau. Functionally, miR-501-3p acts downstream of LINC00641. The cellular effects of LINC00641 overexpression were reversed by co-transfection with miR-501-3p mimic. Overexpression of LINC00641 downregulated miR-501-3p expression, restoring neuronal cell viability and reducing cell damage. Targeting LINC00641 holds potential as a diagnostic biomarker and therapeutic candidate for AD, which requires further validation in animal models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Geriatrics Department, Nantong Hospital of Traditional Chinese Medicine, Nantong City, Jiangsu Province, China.
- Department of Neurology, Wuhan No.9 Hospital, Wuhan City, Hubei Province, China.
- Health Management Center, Shandong Provincial Hospital, Shandong First Medical University, No.324, Jingwu Weiqi Road, Shandong Province, 250021, Jinan City, China. liuyumei2014@163.com.
- Department of Clinical Nutrition, The Thirteenth People's Hospital of Chongqing, No. 16, Railway New Village, Huangjueping Street, Jiulongpo District, 400053, Chongqing, China. Wangwuycq@163.com.
Förderung
- Nantong Municipal Science and Technology Bureau Social Democracy Science and Technology Project
Zitieren
APA
Ren, L., Zhang, W., Liu, Y., & Wang, W. (2026). Value of lncRNA LINC00641 as a Potential Biomarker for Diagnosis of Alzheimer’s Disease and Elucidation of its Underlying Molecular Mechanism. Journal of Molecular Neuroscience, 76(1). https://doi.org/10.1007/s12031-026-02484-2
Vancouver
Ren L, Zhang W, Liu Y, Wang W. Value of lncRNA LINC00641 as a Potential Biomarker for Diagnosis of Alzheimer’s Disease and Elucidation of its Underlying Molecular Mechanism. Journal of Molecular Neuroscience. 2026;76(1). doi:10.1007/s12031-026-02484-2
BibTeX
@article{Ren2026,
author = {Ren, Lihong and Zhang, Wenjun and Liu, Yumei and Wang, Wuying},
title = {Value of lncRNA LINC00641 as a Potential Biomarker for Diagnosis of Alzheimer’s Disease and Elucidation of its Underlying Molecular Mechanism},
journal = {Journal of Molecular Neuroscience},
year = {2026},
volume = {76},
number = {1},
doi = {10.1007/s12031-026-02484-2}
}
EUVIMED